MarketPR
MARKETSTKLF fiscal year 2026 results surface for Tokyo Lifestyle Co.Jul 18MARKETSAres Management moves second-quarter earnings call to 9 a.m. ET on July 31Jul 18MARKETSCNC earnings date set: Centene Corporation to release Q2 2026 results before the bell on July 28Jul 18MARKETSCVS Health (CVS) declares $0.665 quarterly dividend, payable August 3Jul 18MARKETSGeneDx Holdings (WGS) investors face August 3 lead-plaintiff deadline in Robbins Geller class actionJul 18MARKETSGamehaus Holdings in focus after Nasdaq flags minimum bid price deficiencyJul 18MARKETSRichard Hourigan, Inc. offers special deals on Myron L Model 512T5D PoolMeter for saltwater poolsJul 18MARKETSBlack Pearl Equities commences tender offer for all outstanding shares of Selectis HealthJul 18MARKETSHome insurance renewal practices in focus as HelloNation publishes Jim Cornwell's review guideJul 18MARKETSBHM preferred dividends declared for third quarter as board authorizes monthly cash paymentsJul 18MARKETSTKLF fiscal year 2026 results surface for Tokyo Lifestyle Co.Jul 18MARKETSAres Management moves second-quarter earnings call to 9 a.m. ET on July 31Jul 18MARKETSCNC earnings date set: Centene Corporation to release Q2 2026 results before the bell on July 28Jul 18MARKETSCVS Health (CVS) declares $0.665 quarterly dividend, payable August 3Jul 18MARKETSGeneDx Holdings (WGS) investors face August 3 lead-plaintiff deadline in Robbins Geller class actionJul 18MARKETSGamehaus Holdings in focus after Nasdaq flags minimum bid price deficiencyJul 18MARKETSRichard Hourigan, Inc. offers special deals on Myron L Model 512T5D PoolMeter for saltwater poolsJul 18MARKETSBlack Pearl Equities commences tender offer for all outstanding shares of Selectis HealthJul 18MARKETSHome insurance renewal practices in focus as HelloNation publishes Jim Cornwell's review guideJul 18MARKETSBHM preferred dividends declared for third quarter as board authorizes monthly cash paymentsJul 18
NewsMacro

Cebranopadol Heads to Greater China as Adneuris Therapeutics Licenses Pain Compound to Zhejiang Conba Pharmaceutical

An exclusive licensing agreement for cebranopadol, the pain treatment in development at Adneuris Therapeutics, places Zhejiang Conba Pharmaceutical at the center of the compound's Greater China effort. Conba takes on full development and commercialization rights across mainland China, Hong Kong, Macao, and Taiwan. Adneuris framed the deal as an important step toward realizing what it described as the global potential of cebranopadol.

By Mara WhitfieldMacro DeskJuly 14, 20262 min read
Share

Key takeaways

  • Adneuris Therapeutics has granted Zhejiang Conba Pharmaceutical an exclusive license to develop and commercialize the pain compound cebranopadol across Greater China.
  • The license covers all four Greater China territories: mainland China, Hong Kong, Macao, and Taiwan.
  • Conba holds full development and commercialization rights for cebranopadol within the licensed zone, while Adneuris retains all rights outside Greater China.
  • The announcement disclosed no financial terms, milestone payments, or upfront figures.
  • Cebranopadol is being developed for a broadly defined pain indication, with no specific target patient population named for the Greater China program.

An exclusive licensing agreement for cebranopadol, the pain treatment in development at Adneuris Therapeutics, places Zhejiang Conba Pharmaceutical at the center of the compound's Greater China effort. Conba takes on full development and commercialization rights across mainland China, Hong Kong, Macao, and Taiwan. Adneuris framed the deal as an important step toward realizing what it described as the global potential of cebranopadol.

Scope and structure of the license

The license is exclusive, covering the pain indication across all four territories that make up Greater China: mainland China, Hong Kong, Macao, and Taiwan. Zhejiang Conba Pharmaceutical carries both the development program and the commercialization rights within that zone. No financial terms, milestone payments, or upfront figures appear in the announcement.

For Adneuris Therapeutics, the deal delegates Greater China development to Conba while the broader program remains active elsewhere. The exclusive structure gives Conba sole authority over cebranopadol development and commercialization within the licensed zone. Adneuris retains all rights outside Greater China.

The compound and its indication

Cebranopadol is being developed for pain. The indication as stated in the agreement is broad, which gives Conba latitude to build a development program across the full therapeutic area within the licensed territories rather than a narrower sub-type. Adneuris did not specify a target patient population or a tighter clinical focus for the Greater China program in the announcement.

What to watch

The agreement is now in place. The next confirmable step is Zhejiang Conba Pharmaceutical beginning regulatory or clinical activity for cebranopadol in any of the four covered territories. A study submission or regulatory filing in mainland China, Hong Kong, Macao, or Taiwan would be the first concrete signal that cebranopadol is advancing under Conba's direction.

About this story

Filed by the macro desk of MarketPR on July 14, 2026. Source: MarketPR. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

TKLF fiscal year 2026 results surface for Tokyo Lifestyle Co.

Fiscal year 2026 results are in focus for Tokyo Lifestyle Co., Ltd. (Nasdaq: TKLF), a Tokyo-based retailer and wholesaler of Japanese beauty and health products, after the company released its annual print on July 10. The disclosure covers a business whose product mix spans luxur

Mateo Fuentes2 min read
02Macro

Ares Management moves second-quarter earnings call to 9 a.m. ET on July 31

Ares Management Corporation's second-quarter earnings call now opens at 9:00 a.m. ET on Friday, July 31, 2026. The firm flagged the time change from New York on July 10, noting a combined we

Ines Ferreira2 min read
03Macro

CNC earnings date set: Centene Corporation to release Q2 2026 results before the bell on July 28

NYSE: CNC is in focus on the earnings calendar. Centene Corporation, the St. Louis-based healthcare enterprise, confirmed on July 10 that it will release its [2026 second quarter financial

Owen Gallagher2 min read

Frequently asked

What is cebranopadol being developed to treat?

Cebranopadol is being developed for pain, with a broadly stated indication that lets Conba build a program across the full therapeutic area rather than a narrower sub-type.

Which territories does the license cover?

The exclusive license covers the four territories of Greater China: mainland China, Hong Kong, Macao, and Taiwan.

How much is the deal worth?

The announcement did not disclose any financial terms, milestone payments, or upfront figures.

What rights does Adneuris keep?

Adneuris retains all rights to cebranopadol outside of Greater China while delegating development and commercialization within the licensed zone to Conba.

What would be the first sign the deal is progressing?

The first concrete signal would be Zhejiang Conba beginning regulatory or clinical activity, such as a study submission or regulatory filing, in any of the four covered territories.